Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US

Journal of Medical Economics

Volumn 15, Issue 3, 2012, Pages 601-609

  Ivanova, J I ^a   Bergman, R E ^a   Birnbaum, H G ^a   Phillips, A L ^b   Stewart, M ^c   Meletiche, D M ^b  

^a ANALYSIS GROUP   (United States)

^b EMD SERONO INC   (United States)

^c PFIZER INC   (United States)

Author keywords

Adherence; Costs; Disease modifying drugs; Multiple sclerosis; Relapse

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB;

ABSENTEEISM; ADULT; ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE SEVERITY; DRUG COST; EMERGENCY WARD; EMPLOYEE; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SERVICE; MULTIPLE SCLEROSIS; PHARMACY; REIMBURSEMENT; RELAPSE; UNITED STATES;

ADULT; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; EMERGENCY SERVICE, HOSPITAL; EMPLOYMENT; FEMALE; HOSPITALIZATION; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; RECURRENCE; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84859189227     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.667027     Document Type: Article

References (42)

1. Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the Unites States and evidence of an increasing trend in women. Neurology 2002;59:136-8
2. National Multiple Sclerosis Society. ''Who gets MS?''. http://www.nationalmssociety. org/index.aspx. Accessed January 27, 2012
3. Noonan CW, Williamson DM, Henry JP, et al. The prevalence of multiple sclerosis in 3 US communities. Prev Chronic Dis 2010;7:A12. http://www. cdc.gov/pcd/issues/2010/jan/08-0241.htm. Accessed January 27, 2012
4. Pope GC, Urato CJ, Kulas ED, et al. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology 2002; 58:37-43
5. Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm 2002; 8:469-76
6. Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52
7. Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm. 2009;15:543-55
8. Bourdette DN, Prochazka AV, Mitchell W, et al. VA Multiple Sclerosis Rehabilitation Study Group. Health care costs of veterans with multiple sclerosis: Implications for the rehabilitation of MS. Arch Phys Med Rehabil 1993; 74:26-31
9. Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998; 4:419-25
10. Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: A cross-sectional study in the United States. Neurology 2006;66:1696-702
11. Ivanova JI, Birnbaum HG, Samuels S, et al. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US. Pharmacoeconomics 2009;27:681-91
12. National Multiple Sclerosis Society. What is MS? http://www. nationalmssociety. org/about-multiple-sclerosis/what-we-know-about-ms/what-is- ms/index.aspx. Accessed February 1, 2012
13. National Multiple Sclerosis Society. The MS Disease-Modifying Medications General Information. http://www.nationalmssociety.org/about-multiple-sclerosis/ what-we-know-about-ms/treatments/index.aspx. Accessed February 1, 2012
14. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-76
15. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000;6:255-66
16. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39:285-94
17. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997;49:358-63
18. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised doubleblind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
19. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-Term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-36
20. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993;43:655-61
21. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995; 45:1277-85
22. Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of lowdose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther 2007;29:2031-48
23. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899-910
24. Birnbaum HG, Ivanova JI, Samuels S, et al. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: Direct and indirect costs. Curr Med Res Opin 2009;25:869-77
25. Okuda DT, Kozma CM, Dickson M, et al. Relationship between gaps in drug treatment for multiple sclerosis and incidence of exacerbations: Findings from a national managed care database. Poster presented and the International Society for PharmacoEconomics and Outcomes Research 13th Annual International Meeting, Toronto, ON, May 3-7, 2008
26. Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28:51-61
27. Steinberg SC, Faris RJ, Chang CF, et al. Impact of adherence to interferons in the treatment of multiple sclerosis: A non-experimental, retrospective, cohort study. Clin Drug Investig 2010;30:89-100
28. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol 1997; 50:105-16
29. Erickson SR, Coombs JH, Kirking DM, et al. Compliance from self-reported versus pharmacy claims data with metered-dose inhalers. Ann Pharmacother 2001;35:997-1003
30. Pharmacy Quality Alliance. PQA Approved Measures. http://www.pqaalliance. org/files/PQA%20approved%20measures.pdf. Accessed June 28, 2010
31. Bureau of Labor Statistics. Consumer Price Index - All Urban Consumers CUSR0000SAM Seasonally Adjusted U.S. City Average Medical Care. http://data.bls.gov/pdq/SurveyOutputServlet;jsessionidAAC19B5A8C8536 82CCB5F8CC770065FB.tc-instance4. Accessed February 1, 2012
32. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-83
33. Romano PS, Roos LL, Jollis J. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol 1993;46:1075-9
34. National Multiple Sclerosis Society. Symptoms. http://www. nationalmssociety. org/about-multiple-sclerosis/what-we-know-about-ms/symptoms/ index. aspx. Accessed February 1, 2012
35. National Multiple Sclerosis Society. Medications Used in MS. http://www. nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/treatments/ medications/index.aspx. Accessed February 1, 2012
36. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ 1999;18:153-71
37. Blough DK, Ramsey SD. Using generalized linear models to assess medical care costs. Health Serv Outcomes Res Method 2000;1:185-202
38. Brandes DW, Callender T, Lathi E, et al. A review of disease-modifying therapies for MS: Maximizing adherence and minimizing adverse events. Curr Med Res Opin 2009;25:77-92
39. Reynolds MW, Stephen R, Seaman C, et al. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin 2010;26:663-74
40. Tremlett HL, Oger J. Interrupted therapy. Stopping and switching of the -interferons prescribed for MS. Neurology 2003;61:551-4
41. Holland N, Wiesel P, Cavallo P, et al. Adherence to disease-modifying therapy in multiple sclerosis: Part I. Rehab Nurs 2001;26:172-6
42. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009;256:568-76